Hong Li, Yijing Fan, Huiqian Xu, Haihong Qu, Yang Wang, Dandan Yu, Lizhi Zhou
{"title":"不同压力水平的压迫治疗对乳腺癌化疗诱导的周围神经病变的影响：一项随机对照试验。","authors":"Hong Li, Yijing Fan, Huiqian Xu, Haihong Qu, Yang Wang, Dandan Yu, Lizhi Zhou","doi":"10.1016/j.clbc.2025.08.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to examine the effects of compression therapy at different pressure levels on chemotherapy-induced peripheral neuropathy (CIPN).</p><p><strong>Methods: </strong>A total of 108 breast cancer patients who developed CIPN after their first albumin-bound paclitaxel chemotherapy were randomly divided into 3 groups(1:1:1): control group, experimental group 1 (Grade II pressure: 23-32 mmHg), and experimental group 2 (Grade III pressure: 34-46 mmHg). The control group was given standard care, while the experimental groups underwent compression therapy in addition to standard care. CIPN incidence, symptom severity, and its impact on activities of daily living (ADL) were assessed at baseline, after the completion of the third and fifth chemotherapy cycles.</p><p><strong>Results: </strong>After completing 3 chemotherapy cycles, CIPN incidence did not differ significantly among the groups (P > .05). After 5 cycles, the incidence of CIPN (≥ Grade 1) was significantly lower in both experimental groups compared to the control group (P < .05), with Experimental Group 2 also showing lower CIPN incidence (≥ Grade 2) than the control and Experimental Group 1 (P < .05). Both Grade II and III compression therapies alleviated CIPN symptoms and improved ADL, but Experimental Group 2 demonstrated superior efficacy after 5 cycles (P < .05). Significant differences in symptom severity and ADL impact were observed across group, time, and interaction effects (P < .001).</p><p><strong>Conclusion: </strong>Compression therapy reduces CIPN incidence, alleviates symptoms, and improves ADL. Over longer intervention periods, Grade III pressure yields superior outcomes.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effects of Compression Therapy at Different Pressure Levels on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Trial.\",\"authors\":\"Hong Li, Yijing Fan, Huiqian Xu, Haihong Qu, Yang Wang, Dandan Yu, Lizhi Zhou\",\"doi\":\"10.1016/j.clbc.2025.08.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aims to examine the effects of compression therapy at different pressure levels on chemotherapy-induced peripheral neuropathy (CIPN).</p><p><strong>Methods: </strong>A total of 108 breast cancer patients who developed CIPN after their first albumin-bound paclitaxel chemotherapy were randomly divided into 3 groups(1:1:1): control group, experimental group 1 (Grade II pressure: 23-32 mmHg), and experimental group 2 (Grade III pressure: 34-46 mmHg). The control group was given standard care, while the experimental groups underwent compression therapy in addition to standard care. CIPN incidence, symptom severity, and its impact on activities of daily living (ADL) were assessed at baseline, after the completion of the third and fifth chemotherapy cycles.</p><p><strong>Results: </strong>After completing 3 chemotherapy cycles, CIPN incidence did not differ significantly among the groups (P > .05). After 5 cycles, the incidence of CIPN (≥ Grade 1) was significantly lower in both experimental groups compared to the control group (P < .05), with Experimental Group 2 also showing lower CIPN incidence (≥ Grade 2) than the control and Experimental Group 1 (P < .05). Both Grade II and III compression therapies alleviated CIPN symptoms and improved ADL, but Experimental Group 2 demonstrated superior efficacy after 5 cycles (P < .05). Significant differences in symptom severity and ADL impact were observed across group, time, and interaction effects (P < .001).</p><p><strong>Conclusion: </strong>Compression therapy reduces CIPN incidence, alleviates symptoms, and improves ADL. Over longer intervention periods, Grade III pressure yields superior outcomes.</p>\",\"PeriodicalId\":10197,\"journal\":{\"name\":\"Clinical breast cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical breast cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clbc.2025.08.009\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.08.009","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
The Effects of Compression Therapy at Different Pressure Levels on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Trial.
Purpose: This study aims to examine the effects of compression therapy at different pressure levels on chemotherapy-induced peripheral neuropathy (CIPN).
Methods: A total of 108 breast cancer patients who developed CIPN after their first albumin-bound paclitaxel chemotherapy were randomly divided into 3 groups(1:1:1): control group, experimental group 1 (Grade II pressure: 23-32 mmHg), and experimental group 2 (Grade III pressure: 34-46 mmHg). The control group was given standard care, while the experimental groups underwent compression therapy in addition to standard care. CIPN incidence, symptom severity, and its impact on activities of daily living (ADL) were assessed at baseline, after the completion of the third and fifth chemotherapy cycles.
Results: After completing 3 chemotherapy cycles, CIPN incidence did not differ significantly among the groups (P > .05). After 5 cycles, the incidence of CIPN (≥ Grade 1) was significantly lower in both experimental groups compared to the control group (P < .05), with Experimental Group 2 also showing lower CIPN incidence (≥ Grade 2) than the control and Experimental Group 1 (P < .05). Both Grade II and III compression therapies alleviated CIPN symptoms and improved ADL, but Experimental Group 2 demonstrated superior efficacy after 5 cycles (P < .05). Significant differences in symptom severity and ADL impact were observed across group, time, and interaction effects (P < .001).
Conclusion: Compression therapy reduces CIPN incidence, alleviates symptoms, and improves ADL. Over longer intervention periods, Grade III pressure yields superior outcomes.
期刊介绍：
Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
